Arcus Biosciences Inc (NYSE:RCUS) Share Price

Company Profile

Business description
Arcus Biosciences Inc is a clinical-stage biopharmaceutical company. It develops immunotherapies for the treatment of cancer. The company focuses on an ATP-adenosine pathway, which is a key driver of immunosuppression in the tumor microenvironment to create and optimize differentiated small-molecule immuno-oncology product candidates. Its product pipeline includes Domvanalimab, Etrumadenant, AB598, Casdatifan among others. Arcus conducts clinical trials for different types of cancers such as Lung, Colorectal, Pancreatic, and others. The company operates through a single segment which is the business of developing and commercializing immunotherapies.
Contact
3928 Point Eden Way
HaywardCA94545
USA
T: +1 510 694-6200
E: [email protected]
https://www.arcusbio.com
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
674

Recommended

Investors will get to see if the new strategy and capital management framework are working.

Brian Han | 27 January 2026

These undervalued stocks with economic moats have increased their dividends for 25 consecutive years or more.

Susan Dziubinski | 27 January 2026

Central bankers are likely to hold interest rates steady, but Wall Street is focused on life after Powell.

Sarah Hansen | 26 January 2026

Index	Last price	Change	% Change
All Ordinaries	9,250.60	50.70	-0.55%
CAC 40	8,066.68	86.14	-1.06%
DAX 40	24,822.79	71.65	-0.29%
Dow JONES (US)	49,028.92	25.51	0.05%
FTSE 100	10,154.43	53.37	-0.52%
HKSE	27,826.91	699.96	2.58%
NASDAQ	23,849.74	32.64	0.14%
Nikkei 225	53,358.71	25.17	0.05%
NZX 50 Index	13,412.87	98.01	-0.73%
S&P 500	6,976.41	2.19	-0.03%
S&P/ASX 200	8,933.90	40.40	-0.45%
SSE Composite Index	4,151.24	11.33	0.27%